Cost Per Response Analysis of Nivolumab Versus Everolimus in the Treatment of Patients Previously Treated with Advanced Renal Cell Carcinoma – Brazil Private Health Care System Perspective
Oct 1, 2017, 00:00
10.1016/j.jval.2017.08.2579
https://www.valueinhealthjournal.com/article/S1098-3015(17)32913-3/fulltext
Title :
Cost Per Response Analysis of Nivolumab Versus Everolimus in the Treatment of Patients Previously Treated with Advanced Renal Cell Carcinoma – Brazil Private Health Care System Perspective
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)32913-3&doi=10.1016/j.jval.2017.08.2579
First page :
A875
Section Title :
SELECTED HEALTH CARE TREATMENT STUDIES -MEDICAL DEVICE/DIAGNOSTICS
Open access? :
No
Section Order :
2375